Skip to main content
S

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,169 across all filing types
Latest filing 2026-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
仙乐健康科技股份有限公司关于募集资金存放、管理与实际使用情况的专项报告及审核报告（截至2025年12月31日止）
Audit Report / Information Classification · 1% confidence The document is a combined “募集资金存放、管理与实际使用情况专项报告” (special report on deposit, management and actual use of raised funds) together with an independent auditor’s review report issued by Deloitte. It is not a full annual or interim financial report, earnings release, management discussion, or mere announcement—it is the actual special‐purpose report plus the auditor’s opinion. As a standalone audit/review of non-annual financial information (i.e., the use of proceeds report), it best fits the Audit Report / Information category (Code: AR).
2026-04-23 Chinese
2025年董事会工作报告
Management Reports Classification · 1% confidence The document is a standalone “2025年度董事会工作报告” detailing the board’s review of financial results, key operational factors, governance activities (board meetings and committee work), and future focus. While part of the broader annual reporting package, this is not the full annual report or a simple publication notice; rather it is a substantive management‐level report (board perspective) providing detailed discussion of financial performance, business trends, governance actions, and outlook. This aligns most closely with the “Management Reports (MDA)” category.
2026-04-23 Chinese
公司章程（2025年12月）
Regulatory Filings
2026-04-23 Chinese
关于回购注销2025年限制性股票激励计划部分已授予但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 1% confidence The document is an official company announcement detailing the repurchase and cancellation of unvested restricted shares under its 2025 stock incentive plan. It describes the quantity, price, funding source, and procedural approvals for the company’s buyback of its own shares. This fits the definition of “Transaction in Own Shares” (POS), which covers corporate share repurchase activities. It is not a dividend, management change, M&A, or financial report, but clearly a share buyback and cancellation notice.
2026-04-23 Chinese
2026年第一季度报告披露提示性公告
Report Publication Announcement Classification · 1% confidence The document is a brief announcement (“提示性公告”) stating that the 2026 Q1 report was approved at the board meeting and has been published on the stock exchange disclosure website. It contains no financial detail itself and simply directs investors to review the actual report. Under the “menu vs. meal” rule, this short notice of report publication is classified as a Report Publication Announcement (RPA).
2026-04-23 Chinese
关于募集资金存放、管理与实际使用情况的专项报告（截至2025年12月31日）
Capital/Financing Update Classification · 1% confidence The document is a standalone special report prepared by the board of Xianle Health (仙乐健康) on the deposit, management and actual use of proceeds from its 2021 convertible bond issuance, covering amounts raised, account storage, regulatory custodian arrangements, detailed use-of-proceeds tables and changes through 31 December 2025. It is not an earnings release, annual/interim report, audit report, management discussion or AGM material but a regulatory‐required update on the company’s financing proceeds and their usage. This best matches “Capital/Financing Update” (CAP).
2026-04-23 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.